Celcuity (NASDAQ:CELC) Announces Quarterly Earnings Results

Celcuity (NASDAQ:CELC) issued its quarterly earnings data on Thursday. The company reported ($1.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.30, FiscalAI reports.

Here are the key takeaways from Celcuity’s conference call:

• Commercial launch of REVTORPYK is off to a strong early start: within about a month of availability, 78% of Celcuity’s 36 priority accounts had ordered the drug, and 91% of U.S. commercial and Medicare lives were covered. The company also reported a preferred NCCN recommendation and inclusion in three of four major provider pathways.
• VIKTORIA-1 results presented at ESMO showed encouraging efficacy across patient subgroups, including median progression-free survival of 21.5 months for the triplet in patients without liver metastases, and higher response rates than the comparator. Celcuity also highlighted lower treatment-discontinuation rates with gedatolisib regimens, while noting the results are from clinical trials.
• Potential growth extends beyond the current second-line indication: Celcuity expects to submit data for the PIK3CA-mutant cohort to global regulators, is conducting first-line breast cancer trials, and plans a randomized phase II prostate cancer study in the first half of 2027. These programs remain subject to clinical and regulatory outcomes.
• Third-quarter net loss widened to $73.3 million from $43.8 million a year earlier as operating expenses rose, largely reflecting commercial launch investment. Celcuity ended the quarter with $642.7 million in cash, equivalents and short-term investments and said it expects funding through 2029; it reported no product revenue in the quarter.

Celcuity Price Performance

Celcuity stock traded down $5.20 on Thursday, reaching $64.04. The company’s stock had a trading volume of 1,423,630 shares, compared to its average volume of 1,686,345. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -14.89 and a beta of 0.16. The business’s fifty day moving average price is $75.64 and its 200 day moving average price is $99.57. Celcuity has a twelve month low of $53.54 and a twelve month high of $151.02.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CELC shares. Cantor Fitzgerald assumed coverage on shares of Celcuity in a research report on Thursday, October 22nd. They set an “overweight” rating and a $140.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. Citigroup restated a “market outperform” rating on shares of Celcuity in a research report on Monday, October 19th. Wall Street Zen cut shares of Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Stifel Nicolaus dropped their price objective on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $152.57.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.